Zacks Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Zacks Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-150,542	Closed	-$1.05M	–	596
2020 Q4	$1.05M	Sell	150,542 -16,546	-10%	-$129K	0.02%	340
2020 Q3	$1.36M	Sell	167,088 -101,893	-38%	-$632K	0.03%	273
2020 Q2	$1.86M	Sell	268,981 -93,658	-26%	-$505K	0.04%	207
2020 Q1	$1.72M	Buy	362,639 +234,803	+184%	+$1.35M	0.04%	212
2019 Q4	$1.12M	Buy	+127,836	New	+$691K	0.02%	372

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Zacks Investment Management's JNCE Position: Q1 2021 in Review

Zacks Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2021, closing a stake of 150,542 shares — an estimated $1.05M sold.

Zacks Investment Management first reported a position in JNCE in Q4 2019 and held it in 5 quarters. The position peaked at $1.86M in Q2 2020. 124 funds tracked by Wall St. Rank hold JNCE as of Q1 2021.

Zacks Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Zacks Investment Management sold 150,542 Jounce Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.05M.
Zacks Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
Zacks Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $1.86M in Q2 2020.
124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Zacks Investment Management's 13F filing for Q1 2021, filed 17 May 2021.